0
Skip to Content
B+ | Fighting Childhood Cancer B+ | Fighting Childhood Cancer
ABOUT
ABOUT
OVERVIEW
ANDREW'S STORY
CHILDHOOD CANCER FACTS
FINANCIALS
GET INVOLVED
GET INVOLVED
B+ EVENTS
STUDENTS & SCHOOL EVENTS
INDIVIDUAL EVENTS
B+ HEROES
ALUMNI & PROFESSIONALS
PARTNERS & SPONSORS
INVITE JOE TO SPEAK
WAYS TO GIVE
ANDREW'S CHAMPIONS FOR HOPE
RESEARCH
RESEARCH
OVERVIEW
RESEARCH GRANTS
NEED HELP?
NEED HELP
FAMILY ASSISTANCE
PSYCHOSOCIAL SUPPORTS
TESTIMONIALS
BLOG
MERCH
DONATE
B+ | Fighting Childhood Cancer B+ | Fighting Childhood Cancer
ABOUT
ABOUT
OVERVIEW
ANDREW'S STORY
CHILDHOOD CANCER FACTS
FINANCIALS
GET INVOLVED
GET INVOLVED
B+ EVENTS
STUDENTS & SCHOOL EVENTS
INDIVIDUAL EVENTS
B+ HEROES
ALUMNI & PROFESSIONALS
PARTNERS & SPONSORS
INVITE JOE TO SPEAK
WAYS TO GIVE
ANDREW'S CHAMPIONS FOR HOPE
RESEARCH
RESEARCH
OVERVIEW
RESEARCH GRANTS
NEED HELP?
NEED HELP
FAMILY ASSISTANCE
PSYCHOSOCIAL SUPPORTS
TESTIMONIALS
BLOG
MERCH
DONATE
Folder: ABOUT
Folder: GET INVOLVED
Folder: RESEARCH
Folder: NEED HELP?
BLOG
MERCH
DONATE
Back
ABOUT
OVERVIEW
ANDREW'S STORY
CHILDHOOD CANCER FACTS
FINANCIALS
Back
GET INVOLVED
B+ EVENTS
STUDENTS & SCHOOL EVENTS
INDIVIDUAL EVENTS
B+ HEROES
ALUMNI & PROFESSIONALS
PARTNERS & SPONSORS
INVITE JOE TO SPEAK
WAYS TO GIVE
ANDREW'S CHAMPIONS FOR HOPE
Back
RESEARCH
OVERVIEW
RESEARCH GRANTS
Back
NEED HELP
FAMILY ASSISTANCE
PSYCHOSOCIAL SUPPORTS
TESTIMONIALS
Development of a novel radiopharmaceutical agent for non-invasive immunotherapy target detection and CAR T combination therapy in neuroblastoma
Northeast, Maryland Julia Travagline 11/20/24 Northeast, Maryland Julia Travagline 11/20/24

Development of a novel radiopharmaceutical agent for non-invasive immunotherapy target detection and CAR T combination therapy in neuroblastoma

Development of a novel radiopharmaceutical agent for non-invasive immunotherapy target detection and CAR T combination therapy in neuroblastoma

Dr. Rosa Nguyen, M.D., Ph.D. – National Cancer Institute, NIH NCI Pediatric Oncology, Bethesda, MD

Read More
Optimizing Pediatric Cancer Immunotherapy with Nano-Targeted Off-the-Shelf Natural Killer T Cells
South, Florida Julia Travagline 12/14/22 South, Florida Julia Travagline 12/14/22

Optimizing Pediatric Cancer Immunotherapy with Nano-Targeted Off-the-Shelf Natural Killer T Cells

Optimizing Pediatric Cancer Immunotherapy with Nano-Targeted Off-the-Shelf Natural Killer T Cells

University of Miami, Miami, FL

Read More
T cell immunotherapy targeting fusion-derived “public” neoantigens expressed by pediatric desmoplastic small round cell tumors
Northeast, New York Julia Travagline 12/8/21 Northeast, New York Julia Travagline 12/8/21

T cell immunotherapy targeting fusion-derived “public” neoantigens expressed by pediatric desmoplastic small round cell tumors

T cell immunotherapy targeting fusion-derived “public” neoantigens expressed by pediatric desmoplastic small round cell tumors

Memorial Sloan Kettering Cancer Center (MSK), New York, NY

Read More
The role of inflammation in the liver microenvironment of a Fibrolamellar Carcinoma zebrafish model
New York, Northeast Julia Travagline 12/8/21 New York, Northeast Julia Travagline 12/8/21

The role of inflammation in the liver microenvironment of a Fibrolamellar Carcinoma zebrafish model

The role of inflammation in the liver microenvironment of a Fibrolamellar Carcinoma zebrafish model

Albert Einstein College of Medicine, New York, NY

Read More
Overcoming Resistance of CAR T Cells Immunotherapy with CBP/ß-catenin Antagonists in Pediatric Glioma and Ependymoma
California, West Julia Travagline 8/10/21 California, West Julia Travagline 8/10/21

Overcoming Resistance of CAR T Cells Immunotherapy with CBP/ß-catenin Antagonists in Pediatric Glioma and Ependymoma

Overcoming Resistance of CAR T Cells Immunotherapy with CBP/ß-catenin Antagonists in Pediatric Glioma and Ependymoma

Beckman Research Institute of the City of Hope, Duarte, CA

Read More
Boosting Immunovirotherapy with Tumor Vaccination to Treat Pediatric Malignant Brain Tumors
Alabama, South Julia Travagline 8/10/21 Alabama, South Julia Travagline 8/10/21

Boosting Immunovirotherapy with Tumor Vaccination to Treat Pediatric Malignant Brain Tumors

Boosting Immunovirotherapy with Tumor Vaccination to Treat Pediatric Malignant Brain Tumors

University of Alabama at Birmingham, Birmingham, AL

Read More
Preclinical Development of Novel Immunotherapies for Pediatric Acute Myeloid Leukemia (AML)
Pennsylvania, Northeast Julia Travagline 8/9/21 Pennsylvania, Northeast Julia Travagline 8/9/21

Preclinical Development of Novel Immunotherapies for Pediatric Acute Myeloid Leukemia (AML)

Preclinical Development of Novel Immunotherapies for Pediatric Acute Myeloid Leukemia (AML)

Children’s Hospital of Philadelphia, Philadelphia, PA

Read More
Pediatric ALL CAR T-Cell Therapy
Washington, West Julia Travagline 8/9/21 Washington, West Julia Travagline 8/9/21

Pediatric ALL CAR T-Cell Therapy

Pediatric ALL CAR T-Cell Therapy

Seattle Children’s Hospital, Seattle, WA

Read More
Phase I Polio Oncolytic Virotherapy (PVS-RIPO) of Pediatric High-Grade Glioma
North Carolina, South Julia Travagline 8/9/21 North Carolina, South Julia Travagline 8/9/21

Phase I Polio Oncolytic Virotherapy (PVS-RIPO) of Pediatric High-Grade Glioma

Phase I Polio Oncolytic Virotherapy (PVS-RIPO) of Pediatric High-Grade Glioma

Duke University Medical Center, Durham, NC

Read More

HELPFUL LINKS

BLOG

RESEARCH

SCHOOLS

COMPANIES

FACTS

PRIVACY

ABOUT

B+ EVENTS

B+ HEROES

HERO FUNDS

B+ GEAR

GET ASSISTANCE

 

CONNECT WITH US

Address: The B+ Foundation
101 Rockland Circle
Wilmington, DE 19803

Phone: 302.563.8389 | 845.304.6347
Email: Joe@BePositive.org | Carly@BePositive.org

Family Assistance: Katie@BePositive.org | 609.330.6775

 
Today-logo.png
 
ICRP-logo copy.jpg
 

CONTACT US

Name *
Thank you!

 The Andrew McDonough B+ Foundation is an IRS-certified 501(c)3 organization. Our Tax ID # is 42-1741037.

B+® is a registered trademark